Daily Stock Analysis: HP Inc., Monday, Jan. 30
HP Inc bears the ticker symbol (HPQ), and this is my second mention of HP Inc for this new Viking Portfolio. I last talked about HP Inc November 11, 2022.
HP (formerly Hewlett-Packard) is a behemoth in the PC and printing markets. It has focused on these markets since it exited IT infrastructure in 2015 with the split from Hewlett Packard Enterprise.
HP Inc focuses on the commercial market but maintains sales of consumer devices and printers. The firm has a broad and global customer base, with only one-third of sales coming from the U.S. It completely outsources manufacturing and relies heavily on channel partners for its sales and marketing.
The company, as mentioned, was formerly known as Hewlett-Packard Company and changed its name to HP Inc. in October 2015.
HP Inc. was founded in 1939 and is headquartered in Palo Alto, California.
|
HP Inc or any dividend paying firm:
|
At Friday’s $29.24 closing price, a little under $1000 would buy 34 shares.
A $10 broker fee (if charged), paid half at purchase and half at sale, might cost us about $0.29 per share.
Subtract that maybe $0.29 brokerage cost from my estimated $3.21gross gain makes a net gain of $2.92 X 34 shares = $99.28 for an 9.9% net gain including a 3.59% annual dividend yield.
In the next year our $1K investment in shares of HP Inc would generate $35.90 in cash dividends. Of course, a single share of HPQ stock at Friday’s $29.24 price is nearly 1.25 times less than the estimated annual dividend income from our $1000.00 investment.
So, by my dogcatcher ideal, this could be a good time to buy HP Inc shares based on their dividends for 2023. The current dividend from $1K invested is $6.66 greater than the HPQ single share price. Consider yourself alerted.
All of the estimates above are speculation based on the past history of investment in shares of HP Inc. Only time and money invested in this stock will determine its future market value.
More By This Author:
Daily Stock Analysis: Medical Facilities
Stock Analysis: Viatris
Stock Analysis: Takeda Pharmaceutical
Disclaimer: This article is for informational and educational purposes only and should not be construed to constitute investment advice. Nothing contained herein shall constitute a ...
more